AI Chat
Loading data for NVAX — first visit, this takes a few seconds.

Novavax, Inc.

NVAX · NasdaqGS · USD

9.26 +0.21 (2.32%)

At close: Sep 11, 2026, 8:00 PM

9.50 +0.85%

After-hours: 7:59 PM

Market Cap
$1.55B
Volume
4.2M
Next earnings date
Nov 5, 2026

Novavax, Inc. (NVAX) Stock Price, Analysis & Data

Intrinsic Value

Loading intrinsic value…

Analyst Forecast

Stock Forecasts →

Analyst forecast unavailable

12-month target · n/a analysts

Analyst Consensus: n/a

Interval:1D
Loading candles and signals…

Financial Performance

View financials →

Loading...

Latest Earnings

ReportedVs estimateYoY Change
Revenue$56.70Mn/a-76.30%
EPS-$0,32+$0,06-151.61%

Next Earnings

before market opens.

Estimate · Upgrade →

View earnings details →

Metrics

Bid
6.59
Net Income (ttm)
-248M
2.45
-1.53
n/a
-15.34
P/B (ttm)
-8.14
P/S (ttm)
3.75
Earnings Date
Nov 5, 2026
Ask
11
Volume
4,196,996
Avg. Volume (20D)
4,095,785
Open
9.18
Previous Close
9.05
Day's Range
8.89 - 9.34
52-Week Range
6.20 - 11.97
Ex-Dividend Date
n/a

About Novavax, Inc.

View profile →
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Biotechnology · Healthcare

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 1995
Employees 749
Stock Exchange NasdaqGS
Ticker Symbol NVAX